NDAINTRAVENOUSPOWDERPriority Review
Approved
Jul 2014
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
10
Mechanism of Action
Histone Deacetylase Inhibitors
Pharmacologic Class:
Histone Deacetylase Inhibitor
Indications (2)
Clinical Trials (5)
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Started Oct 2023
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
Started Dec 2021
7 enrolled
Metastatic Uveal Melanoma
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
Started May 2021
34 enrolled
Metastatic Breast CancerRecurrent Ovarian Carcinoma
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
Started Mar 2021
26 enrolled
Metastatic Breast CancerMetastatic Castration-resistant Prostate CancerMetastatic Ovarian Carcinoma+1 more
Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation
Started Oct 2020
0Metastatic Adenocarcinoma
Loss of Exclusivity
LOE Date
Oct 27, 2027
20 months away
Patent Expiry
Oct 27, 2027